Can Prozac (fluoxetine) cause urinary retention?

Can Prozac (Fluoxetine) Cause Urinary Retention?

Yes, Prozac (fluoxetine) can cause urinary retention, though this is an uncommon side effect that warrants clinical awareness and monitoring.

Evidence from FDA Drug Labeling

The official FDA drug label for Prozac does not explicitly list urinary retention as a common adverse event in the standardized COSTART Dictionary adverse event tables 1. However, the absence from common adverse event tables (which typically report events occurring in ≥2% of patients) does not mean the side effect doesn't occur—it indicates it happens at lower frequencies.

Real-World Evidence and Pharmacovigilance Data

The most robust recent evidence comes from a 2024 pharmacovigilance study analyzing the FDA Adverse Event Reporting System (FAERS) database from 2004 to Q1 2024 2. This large-scale analysis of 17,785,793 adverse events identified:

• Fluoxetine showed a significant signal for urinary retention with disproportionality analysis
• The signal was validated across both FDA and Canadian databases
• Median time to onset of urinary retention was 29 days, with over half of cases occurring within 30 days of starting medication
• This represents new signal detection for fluoxetine, as urinary retention was not previously well-recognized in drug labeling

Clinical Case Evidence

Multiple case reports document fluoxetine-induced urinary retention:

• A 2022 case report described chronic urinary retention in a 15-year-old girl on fluoxetine monotherapy that resolved completely after discontinuation 3
• A 2001 case documented urinary retention after fluoxetine-risperidone combination, though the interaction complicates attribution 4
• Even veterinary medicine has documented this effect, with a 2022 report of fluoxetine-induced urinary retention in a cat that resolved after drug discontinuation 5

Systematic Review Findings

A 2016 systematic review examining urinary retention with antidepressants found 6:

• Urinary retention occurred in 0.025% of patients on SSRIs (including fluoxetine)
• This rate is substantially lower than tricyclic antidepressants (17.6% on imipramine)
• The majority of case reports showed improvement with discontinuation or dose reduction

A 2021 meta-analysis confirmed that SSRIs like fluoxetine primarily cause voiding disorders rather than storage symptoms, with lower odds ratios compared to tricyclic antidepressants and SNRIs 7.

Mechanism and Clinical Context

The mechanism likely involves:

• Serotonergic effects on bladder function through central nervous system pathways
• Possible anticholinergic activity, though fluoxetine has minimal anticholinergic properties compared to tricyclics
• Individual patient susceptibility factors

Clinical Recommendations

When prescribing fluoxetine:

1. Screen for baseline urinary symptoms before initiating therapy, particularly in:

   • Elderly patients (who have higher baseline risk)
   • Males with benign prostatic hyperplasia
   • Patients on other medications affecting bladder function (anticholinergics, alpha-agonists)

2. Monitor actively during the first 30 days of treatment, as this is when most cases occur 2

3. If urinary retention develops:

   • Discontinue fluoxetine as first-line management
   • Expect resolution within days to weeks after discontinuation 3, 5
   • Consider alternative antidepressants with lower urinary risk profiles

4. Document the adverse event to contribute to pharmacovigilance databases

Important Caveats

• While urinary retention with fluoxetine is uncommon (0.025% incidence), it is clinically significant when it occurs and requires prompt recognition
• The risk is substantially lower than with tricyclic antidepressants but still present
• Do not assume urinary symptoms are unrelated to fluoxetine simply because they're not listed as common side effects in the package insert
• The 2024 pharmacovigilance data represents the strongest evidence to date and suggests this side effect may be underrecognized 2